Indivior PLC (LSE:INDV) - Share price


Stock Report

Indivior PLC INDV

Last Price
GBX297.00

Day Change
2.00|0.68%

As of 16/05/2022
18:04:05 BST | GBX
Minimum 15 Minutes Delay.

Last Close295.00p
Day Range290.60 - 299.00
Mkt Cap2.09Bil
52-Wk Range143.60 - 340.00
Yield %-
ISINGB00BRS65X63
Volume1,010,727
P/E15.65
P/S2.89
P/CF6.48

Share Price

Total Returns 16/05/2022

 Chg (%)  
More ...
Indivior PLC-9.40 
FTSE 100 TR GBP-1.70
 
Financials
201920202021
More ...
Income Statement
Turnover785.00647.00791.00
Operating Profit178.00-156.00181.00
Net Profit134.00-148.00205.00
Reported EPS0.18-0.200.27
Balance Sheet
Current Assets1,360.001,187.001,444.00
Non Current Assets292.00344.00388.00
Total Assets1,652.001,531.001,832.00
Current Liabilities742.00599.00804.00
Total Liabilities1,443.001,449.001,629.00
Total Equity209.0082.00203.00
Cash Flow
Operating Cash Flow133.00-159.00371.00
Net Change in Cash136.00-207.00245.00

Regulatory News

DateAuthor Headline
11/07/2019James Gard Reckitt Shares Rise After Suboxone Settlement
Consumer giant settles with US regulators over the marketing of an opioid addiction drug Suboxone by former subsidiary Invidior
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
14/03/2022Transfer inMr. Mark Wesley Crossley0.00103,4990.00
07/03/2022Transfer inMr. Ryan Preblick0.0056,8950.00
07/03/2022SaleMr. Ryan Preblick257.3025,66066,023.00
29/11/2021Transfer inMr. Ryan Preblick0.0058,9990.00

Company Profile

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE 250 , FTSE 350 , FTSE All Share

Next Event 29/07/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)16.97
Div Yld (E)0.00
PEG (E)0.00
ROCE21.01
Op Mrgn0.23
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Date18/09/1517/06/16
Ex-Div17/09/1516/06/16
Paid23/10/1529/07/16
Amnt2.087.30
Directors
More ...
Non-Executive Director, ChairmanMr. Graham Charles Hetherington
Non-Executive DirectorMr. Daniel Joseph Phelan
Non-Executive DirectorMr. Mark Stejbach
Non-Executive DirectorDr. Peter James Jonathan Bains
Non-Executive DirectorMr. Jerome J Lande
Non-Executive DirectorMs. Lorna Mary Southcombe Parker
Non-Executive DirectorDr. Andrew Thomas McLellan
Executive Director, Chief Executive OfficerMr. Mark Wesley Crossley
Executive Director, Chief Financial OfficerMr. Ryan Preblick
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.